Recent Tesamorelin Research — VialBase Research
Ongoing investigation of tesamorelin applications beyond HIV lipodystrophy
- Ongoing investigation of tesamorelin applications beyond HIV lipodystrophy
- Interest in metabolic syndrome, NAFLD, and body composition applications
⚠️ [PMID unverified — flagged 2026-06-19] — PMID 41476424 resolves to Mayfield CK et al., Am J Sports Med 2026, “Injectable Peptide Therapy: A Primer” — a generic review reused across multiple research notes, not a tesamorelin-specific study. (A candidate tesamorelin meta-analysis, PMID 41545261, exists as a separate note but was not confirmed as this note’s source.) Treat this PMID as unverified.
PMID 41476424 — Recent Tesamorelin Research
Compound: Tesamorelin Citation: PubMed
Summary
Recent research publication on tesamorelin, contributing to the growing evidence base for GHRH analog applications. Expands understanding of tesamorelin’s metabolic and body composition effects.
See Also
- Parent compound: Tesamorelin
Save 15% with code VIALBASE
VialBase may earn a commission on partner links — never at extra cost to you. Disclosure.